NCT01387204View on ClinicalTrials.gov

Study to Investigate the Absorption, Distribution, Metabolism and Elimination of [14C]GSK1120212

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 15, 2011

Primary Completion Date

July 18, 2011

Study Completion Date

July 18, 2011

Conditions

Cancer

Interventions

DRUG

GSK1120212

The 2 mg dose is based on clinical data from the ongoing FTIH study in which subjects have been dosed daily for greater than 21 days, as well as preclinical toxicity data.

Trial Locations (1)

98418

GSK Investigational Site, Tacoma